Literature DB >> 7979287

Effects of dirithromycin and erythromycylamine on human neutrophil degranulation.

H Abdelghaffar1, E M Mtairag, M T Labro.   

Abstract

Dirithromycin and, to a lesser extent, erythromycylamine and erythromycin directly induced the release of three intragranular enzymes (lysozyme, lactoferrin, and beta-glucuronidase) from unstimulated human neutrophils. Macrolide-induced enzyme release was dependent upon the incubation time (30 to 180 min) and drug concentration. Dirithromycin was the most effective. At 120 min, release of lysozyme, beta-glucuronidase, and lactoferrin by macrolide (100 micrograms/ml)-treated cells, expressed as a percentage of total enzyme content, was, respectively, 58% +/- 8.3%, 52% +/- 10.7%, and 35% +/- 5.1% (dirithromycin); 42% +/- 3.9%, 28% +/- 5.8%, and 10% +/- 2.2% (erythromycylamine); and 35% +/- 4.0%, 19% +/- 4.3%, and 10% +/- 5.2% (erythromycin) (mean +/- standard error of the mean of three to eight experiments). The lowest macrolide concentrations which induced significant enzyme release were 10, 100, and 25 micrograms/ml, respectively, for dirithromycin, erythromycylamine, and erythromycin. Furthermore, we obtained evidence of a link between the prodegranulation effects of dirithromycin and erythromycylamine and the intragranular location of these drugs. Indeed, cell-associated drug levels increased for up to 60 min and then plateaued and declined substantially. Increasing the pH from 7 to 9 resulted in a parallel increase in drug uptake and the prodegranulation effect. Finally, when macrolide-treated neutrophils were disrupted by sonication and centrifuged, a correlation was found between lysozyme and beta-glucuronidase activities (both granule markers) and pellet-associated macrolide levels. Taken together, our results suggest that dirithromycin and erythromycylamine concentrate within neutrophil granules and then induce degranulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979287      PMCID: PMC284591          DOI: 10.1128/AAC.38.7.1548

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils.

Authors:  M T Labro; J el Benna; C Babin-Chevaye
Journal:  J Antimicrob Chemother       Date:  1989-10       Impact factor: 5.790

2.  Selective secretion of azurophil granule contents induced by monovalent cation ionophores in human neutrophils: evidence for direct ionophore effects on the granule membrane.

Authors:  C Fittschen; P M Henson
Journal:  J Leukoc Biol       Date:  1991-11       Impact factor: 4.962

3.  Internal pH of human neutrophil lysosomes.

Authors:  B Styrt; M S Klempner
Journal:  FEBS Lett       Date:  1982-11-22       Impact factor: 4.124

4.  An enzyme-linked immunoassay (ELISA) for measurement of lactoferrin.

Authors:  S V Hetherington; J K Spitznagel; P G Quie
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes.

Authors:  O Carević; S Djokić
Journal:  Agents Actions       Date:  1988-08

6.  Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro.

Authors:  E M Mtairag; H Abdelghaffar; M T Labro
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

7.  Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila.

Authors:  M F Miller; J R Martin; P Johnson; J T Ulrich; E J Rdzok; P Billing
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

8.  Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells.

Authors:  M B Carlier; A Zenebergh; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

9.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.

Authors:  E J Bowman; A Siebers; K Altendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent.

Authors:  R Anderson; G Joone; C E van Rensburg
Journal:  J Antimicrob Chemother       Date:  1988-12       Impact factor: 5.790

View more
  7 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Preira; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

3.  Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors.

Authors:  T Kohyama; H Takizawa; S Kawasaki; N Akiyama; M Sato; K Ito
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro.

Authors:  C Feldman; R Anderson; A J Theron; G Ramafi; P J Cole; R Wilson
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

Review 5.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

6.  Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides.

Authors:  E M Mtairag; H Abdelghaffar; C Douhet; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

Review 7.  The immunomodulatory effects of macrolide antibiotics in respiratory disease.

Authors:  Jennifer Pollock; James D Chalmers
Journal:  Pulm Pharmacol Ther       Date:  2021-11-03       Impact factor: 3.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.